Advertisement
Australia markets closed
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • AUD/USD

    0.6615
    -0.0006 (-0.09%)
     
  • OIL

    79.71
    +0.45 (+0.57%)
     
  • GOLD

    2,373.10
    +32.80 (+1.40%)
     
  • Bitcoin AUD

    95,098.27
    +2,575.86 (+2.78%)
     
  • CMC Crypto 200

    1,304.00
    -54.01 (-3.98%)
     
  • AUD/EUR

    0.6132
    -0.0006 (-0.10%)
     
  • AUD/NZD

    1.0971
    +0.0003 (+0.03%)
     
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NASDAQ

    18,212.94
    +99.47 (+0.55%)
     
  • FTSE

    8,434.91
    +53.56 (+0.64%)
     
  • Dow Jones

    39,525.64
    +137.88 (+0.35%)
     
  • DAX

    18,776.45
    +89.85 (+0.48%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

These 2 Numbers Could Spell Trouble for AbbVie Stock

These 2 Numbers Could Spell Trouble for AbbVie Stock

AbbVie (NYSE: ABBV) investors might have a reason to start sweating. After a somewhat weak first quarter, the biopharma company's near future looks like it'll be one with a bit less revenue than expected.